|
|
|
|
|
|
|
04.11.26 - 13:48
|
Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Zimmer Biomet Holdings, Inc. (ZBH), a medical technology company, on Wednesday reported lower profit for the third quarter, compared with the prior year quarter. Further, th......
|
|
|
04.11.26 - 13:02
|
Zimmer Biomet Holdings Inc. Q3 Profit Declines (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Zimmer Biomet Holdings Inc. (ZBH) released earnings for third quarter that Drops, from last yearThe company's earnings came in at $191.6 million, or $1.00 per share. This co......
|
|
|
|
|
04.11.26 - 12:33
|
Zimmer Biomet Announces Third Quarter 2026 Financial Results (PR Newswire)
|
|
|
Third quarter net sales of $2.063 billion increased 3.1% on a reported basis and 3.7% on a constant currency1 basis Third quarter diluted earnings per share were $1.00, a decrease of 13.8%; adjusted1 diluted earnings per share were $1.90, consistent with the prior year period Company......
|
|
|
|
|
02.11.26 - 08:18
|
Morten Henneveld appointed interim CEO of Atlas Antibodies (Cision)
|
|
|
The Board of Atlas Antibodies and Dan Pitulia have mutually agreed that Dan will leave his position as the CEO of the Atlas Antibodies Group.
Morten Henneveld has assumed the role of interim CEO as of November 1, 2026. Morten was most recently CEO of OssDsign and prior to that held leadership positions at GN Group, Zimmer Biomet and Coloplast.
“We thank Dan for his leadership, and we look forward to partnering with Morten and the team as we embark on the next chapter together. His extensive leadership experience and track record of driving strategic change will be instrumental...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.10.26 - 14:12
|
VB Spine Appoints Thomas E. Oglesby as New Chief Financial Officer (Business Wire)
|
|
|
Veteran medtech finance executive brings more than two decades of spine and M&A leadership experienceNEW YORK--(BUSINESS WIRE)--VB Spine LLC (“VB Spineˮ), the largest privately held spine company, today announced the appointment of Thomas E. Oglesby as Chief Financial Officer, effective Sept. 16, 2026. Oglesby joins VB Spine from Zimmer Biomet, where he most recently served as Vice President, Finance for the company's Sports, Extremities and Trauma global business unit.
In his new role, Oglesby will lead VB Spine's finance organization and partner with the executive team on strategy, capital allocation, and continued growth of the company's spine portfolio.
“Thomasʼs deep spine industry knowledge, hands-on operating experience, and proven track record leading finance through periods of significant growth and transformation make him an excellent fit for this role,ˮ said Anthony Viscogliosi, co-CEO of VB Spine, speaking on behalf of his brothers, Marc and John Viscogliosi. “As we continue to exp...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
